Back to mobile site
Get it on Google Play

Sol-Gel completes patient phase of SGT-610 Gorlin syndrome trial

September 17, 2026 8:30 AM EDT Send to a Friend
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) announced that the last patient has completed the final scheduled study visit in its pivotal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login